Listen to our latest Investing Matters Podcast episode 'Uncovering opportunities with investment trusts' with The AIC's Richard Stone here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksCroda International Regulatory News (CRDA)

Share Price Information for Croda International (CRDA)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 4,065.00
Bid: 4,060.00
Ask: 4,061.00
Change: 38.00 (0.94%)
Spread: 1.00 (0.025%)
Open: 4,049.00
High: 4,077.00
Low: 4,022.00
Prev. Close: 4,027.00
CRDA Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Board Appointment

6 Feb 2012 14:00

RNS Number : 8693W
Croda International PLC
06 February 2012
 



6 February 2012

 

Croda International Plc

 

Appointment of Chief Technology Officer

Croda International Plc, the speciality chemicals company, is pleased to announce that Keith Layden has been appointed to the Board as an executive director with immediate effect, in the new role of Chief Technology Officer.

Keith joined Croda in 1984 and for the past 7 years has been President of our Enterprise Technology and Actives businesses, where he has overseen significant growth in innovation and expansion into new product areas. Prior to this he held a number of Managing Director roles across our European business. As Chief Technology Officer, Keith will be responsible for accelerating the identification, development, licensing and acquisition of innovative technologies, the global co-ordination of Croda's R&D activities and the development of novel production processes for our major existing core product platforms.

Steve Foots, Croda's Chief Executive, commented,

"Keith's appointment to the Board is recognition of the importance the capture of external technologies is to our short and medium term growth plans. This is an exciting new role for Keith and the organisation."

Martin Flower, Croda's Chairman, commented,

 "We are delighted that Keith has joined the Croda Board in this important new role. His wealth of experience of the chemical industry and its related technologies will be of great value during the next phase of Croda's development. "

 

There are no further matters to be disclosed under LR9.6.13R of the Listing Rules of the UK Listing Authority.

Enquiries:

Ben Foster, Pendomer Communications

020 3603 5221

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
BOABXGDDCBGBGDL
Date   Source Headline
12th Sep 20238:56 amRNSDirector/PDMR Shareholding
11th Aug 20232:26 pmRNSDirector/PDMR Shareholding
1st Aug 20237:13 amRNSDirector Declaration
25th Jul 20237:00 amRNSResults for the six months ended 30 June 2023
11th Jul 20232:57 pmRNSDirector/PDMR Shareholding
4th Jul 20238:02 amRNSCroda completes acquisition of Solus Biotech
26th Jun 202310:46 amRNSHolding(s) in Company
13th Jun 20233:55 pmRNSDirector/PDMR Shareholding
12th Jun 20232:06 pmRNSDirector/PDMR Shareholding
9th Jun 20237:00 amRNSTrading update
31st May 20232:47 pmRNSDirector/PDMR Shareholding
26th May 20233:51 pmRNSDirector/PDMR Shareholding
11th May 20234:05 pmRNSDirector/PDMR Shareholding
3rd May 20233:08 pmRNSDirector/PDMR Shareholding
3rd May 20233:00 pmRNSDirector/PDMR Shareholding
2nd May 20232:30 pmRNSDirector/PDMR Shareholding
27th Apr 20239:18 amRNSResult of AGM
24th Apr 20234:49 pmRNSDirector/PDMR Shareholding
12th Apr 20232:00 pmRNSDirector/PDMR Shareholding
28th Mar 20233:51 pmRNSDirector/PDMR Shareholding
28th Mar 20233:50 pmRNSDirector/PDMR Shareholding
28th Mar 20233:47 pmRNSDirector/PDMR Shareholding
28th Mar 20233:46 pmRNSDirector/PDMR Shareholding
28th Mar 20233:44 pmRNSDirector/PDMR Shareholding
28th Mar 20233:42 pmRNSDirector/PDMR Shareholding
28th Mar 20233:41 pmRNSDirector/PDMR Shareholding
28th Mar 20233:41 pmRNSDirector/PDMR Shareholding
27th Mar 20233:52 pmRNSDirector/PDMR Shareholding
27th Mar 20233:48 pmRNSDirector/PDMR Shareholding
24th Mar 202310:57 amRNSDirector/PDMR Shareholding
24th Mar 202310:31 amRNSDirectorate Change
17th Mar 20235:12 pmRNSAnnual Financial Report
17th Mar 20232:30 pmRNSDirector/PDMR Shareholding
17th Mar 202310:53 amRNSDirector/PDMR Shareholding
13th Mar 20232:02 pmRNSDirector/PDMR Shareholding
3rd Mar 202311:57 amRNSDirector/PDMR Shareholding
28th Feb 20239:21 amRNSDirectorate Change
28th Feb 20237:00 amRNSResults for the year ended 31 December 2022
13th Feb 20232:14 pmRNSDirector/PDMR Shareholding
6th Feb 20237:00 amRNSAcquisition of Solus Biotech
11th Jan 20233:45 pmRNSDirector/PDMR Shareholding
13th Dec 20223:04 pmRNSDirector/PDMR Shareholding
6th Dec 202212:36 pmRNSDirector/PDMR Shareholding
14th Nov 20223:33 pmRNSHolding(s) in Company
11th Nov 20222:04 pmRNSDirector/PDMR Shareholding
11th Nov 202210:37 amRNSDirector/PDMR Shareholding
11th Nov 202210:33 amRNSDirector/PDMR Shareholding
8th Nov 202211:23 amRNSDirector/PDMR Shareholding
7th Nov 20226:11 pmRNSDirector/PDMR Shareholding
7th Nov 20227:00 amRNSJez Maiden to retire as Group Finance Director

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.